Ambitious Regeneron unveils mixed PhIII results for gout drug

Inspired by a string of development failures, Tarrytown, NY-based Regeneron Pharmaceuticals is endeavoring to find out if it can duplicate the ambitious R&D strategy that made Genentech a star in the biotech world. And if the developer can bring in approvals on all three of its drug programs now in late-stage development, analysts estimate the potential reward at $2 billion in annual revenue. This morning, Regeneron Pharmaceuticals announced that its gout drug...